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decrease in its activity leads to hyperhomocyteinaemia 
(Sumner et al, 1996). With vitamin B12 or folate deficiency, 
serum total homocysteine levels increase because methio­
nine synthase requii'es both cofactors. Morrison et al (1996) 
reported that low concentrations of folate are associated 
with an increased risk of fatal coronary heart disease. 
Megaloblastic anaemia due to folate or B12 deficiency can 
be associated with thromboembolic disease (Balias et al,
1976).
Patients with sickle cell disease typically have hyperactive 
bone marrow as a compensatory mechanism for chronic 
haemolysis. This increases the demand for folic acid and may 
lead to folate deficiency especially in those patients with poor 
dietary intake of folate-rich diets. Patients with sickle cell 
disease usually take 1 mg of folic acid orally every day in 
order to support and maintain their effective erythropoiesis 
and decrease the chances of developing folate deficiency that 
would worsen their anaemia.
We believe that treatment of patients with sickle cell 
disease with daily folic acid provides three benefits. First, it 
maintains effective erythropoiesis with a stable haemoglobin 
level. Second, it prevents the development of folate deficiency 
and the accumulation of homocysteine that may predispose 
to thrombotic events leading to painful episodes. Third, it 
prevents neural tube defects in infants whose mothers have 
had a previous pregnancy resulting in a fetus or an infant 
with such defects (MRC Vitamin Study Research Group, 
1991). Treatment with folic acid costs less than 5 cents/mg/d 
in the Philadelphia area. It must be emphasized, however, that 
the serum concentration of vitamin B12 should be assessed 
prior to folate administration, especially in the presence of 
macrocytosis. Failure to do so may mask megaloblastic 
anaemia due to B12 deficiency by folate therapy.
Heterogeneity in the severity and frequency of sickle cell 
painful episodes is multifactorial. Chronic or intermittent 
folate deficiency may be one factor contributing to this 
heterogeneity. Fullerton et al (1965) reported that pregnant 
patients who had haemoglobin SC disease and megaloblastic 
anaemia had a higher mortality rate and more thrombotic 
complications than those who received adequate prenatal 
care with iron and folic acid. Needless to say, the role of folic 
acid in the prevention of vaso-occlusion in sickle cell disease
needs further study. Nevertheless, folic acid supplementation 
for patients with siclde cell disease is harmless, cost effective, 
and may decrease the morbidity associated with this disease. 
Managed care advocates, undoubtedly, will hail such a 
recommendation.
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ABSENCE OF HEPATITIS C VIRUS INFECTION IN NON-HODGKIN’S LYMPHOMA
Recently it has been suggested that hepatitis C virus (HCV), 
which is both a hepatotropic and a lymphotropic virus (Ferri 
et al, 1993), is associated with non-Hodgkin’s lymphomas 
(NHL), especially B-cell lymphomas of low-grade malignancy 
(Luppi et al, 1996). Serological findings showed a HCV 
positivity in patients with NHL as high as 28-42% (Luppi et al, 
1996; Mazzaro et al, 1996; Ferri et al, 1994). The mechanism 
of this association is still unknown. A possible direct oncogenic 
effect has been suggested because several cases of hepato­
cellular carcinoma in patients with HCV infection, without 
preceding cirrhosis, have been described (de Mitri et al, 1995). 
However, HCV is not endowed with oncogenes or reverse
transcriptase, enabling genome integration, and consequently 
research was focused on the possible oncogenic or prolif­
erative effect of viral proteins.
On the other hand, Brind et al (1996) reported that HCV is 
an uncommon contributory factor for the development of NHL 
in the U.K.: none of the 63 patients with NHL screened for HCV 
infection were positive with the ELISA test. A possible explan­
ation for the discrepancy between these studies is the fact that 
HCV is much more common in Italy than in the British 
population. Either there is no association between HCV and the 
development of NHL in the U.K., or the association is more
to demonstrate because of a low prevalence of HCV.
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Table I. Characteristics of the study group of 115 patients, seronegative with. ELISA
n %
Anti-HCV positivity 0 0
Anti-HBV positivity 0 0
Male:female 66:49 57:43
Histology NHL
Low-grade 51 44
Intermediate-grade 42 37
High-grade 22 19
B-cell origin 99 86
T-cell origin 15 13
Unclassifiable 1 1
Previous interferon alpha treatment 8 7
Previous or concurrent immunosuppressive drugs 88 77
Low WBC count (<1-0 x 109/1)* 9 8
Elevated ALT levels (>3 0 U/l)* 13 11
Blood transfusion before 1989 5 4
None of these factors 27 23
* At the time of HCV testing.
Stimulated by the previous findings, we investigated the 
seroprevalence of HCV infection in all 115 unselected 
patients with NHL who visited our outpatient Haematology 
clinic, in the East Netherlands, during a 6-week period. The 
study group included 2 7 previously untreated patients and 
88 patients on treatment or in remission after treatment. 
ALT levels, a history of blood transfusion, use of immuno­
suppressive drugs, white blood cell count and previous use of 
interferon alpha were recorded.
Diagnosis of NHL was made using standard techniques 
and the lymphomas were classified according to the 
International Working Formulation. B-cell origin was 
demonstrated in 99 NHL (86%) and T-cell origin in 15 
(13%). One case could not be classified. The grade of 
malignancy was low in 51 (44%), intermediate in 42 (37%) 
and high in 22 (19%). HCV antibodies were detected by 
Second-Generation Enzyme Immunoassay: IMx HCV (com­
mercially available kit, Abbott). In case of a positive result an 
additional confirmatory test was performed (RIBA; Chiron 
Corp. Emeryville, Calif.). Hepatitis B virus serology markers 
were detected by ELISA using commercially available kits: 
IMx HBV (Abbott).
Table I summarizes characteristics of the study popula­
tion. The mean age of the patients at the time of HCV-testing
patient who had a positive ELISA test was negative at the RIBA 
confirmatory test. Negative serologic results in HCV infected 
patients may be a consequence of immunosuppression due to 
therapy. However, only nine patients had reduced white blood 
cell counts at the time of HCV diagnosis. Only 17 patients had 
elevated ALT levels and/ or a history of blood transfusion before 
1989. These patients were also seronegative.
Our data do not support an association between HCV 
infection and B-cell NHL in our region. It is possible that 
other factors associated with HCV or specific HCV subtypes 
are responsible for the presumed association 
Further studies are required to investigate the 
of HCV in the development of NHL in different 
areas, taking into account viral characteristics.
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was 53 ± 15 years (range 19-84). 44% of NHL cases were 
classified as low-grade malignant lymphomas, which is the 
subgroup HCV has previously been associated with.
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ABSENCE OF KAPOSI’S SARCOMA ASSOCIATED HERPESVIRUS-LIKE DNA SEQUENCES (KSHV) 
IN HIV-NEGATIVE MULTICENTRIC CASTLEMAN’S DISEASE COMPLICATED BY KSHV-POSITIVE 
KAPOSI’S SARCOMA
Herpesvirus-like DNA sequences (KSHV) were first detected subsequently been demonstrated in body cavity based 
in Kaposi’s sarcoma (Chang et al, 1994; Moore & Chang, lymphomas (Cesarman et al, 1995). Recently, KSHV has 
1995; Huang et al, 1995; Dupin et al, 1995), and have also been found in multicentric Castleman’s disease
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